A New Era in Lung Cancer Treatment. Non-small cell lung cancer (NSCLC) is the most common and deadly form of lung cancer. Over the past two decades, advances in molecular profiling have revealed that many NSCLCs are driven by specific gene mutations, making them amenable to precision targeted therapies rather than one-size-fits-all chemotherapy.
The Concept of Oncogene Addiction. Cancers driven by a single overactive gene mutation are said to be 'oncogene-addicted' - they depend on that one pathway to survive and grow. This dependency is actually a vulnerability: drugs that block the mutant protein can be remarkably effective, often shrinking tumors dramatically in patients whose cancers have the relevant mutation.
Actionable Mutations Identified. Key driver mutations in NSCLC include EGFR, ALK, KRAS, ROS1, RET, MET, BRAF, HER2, NTRK, and FGFR. Among these, EGFR mutations are the most prevalent, affecting up to 60% of Asian patients with advanced NSCLC, while KRAS G12C is most common in Western patients at 10-13% of advanced non-squamous NSCLC cases.
Why This Matters for Patients. Targeted therapies have transformed stage IV NSCLC from a uniformly fatal disease into one where some patients achieve years of disease control. Early-stage patients with certain mutations can now receive targeted drugs after surgery to prevent recurrence, extending disease-free survival dramatically compared to chemotherapy alone.
Diversity of Driver Mutations. Next-generation sequencing has revealed that NSCLC is not one disease but many, each defined by distinct molecular drivers. EGFR mutations (primarily exon 19 deletions and L858R) are most common in Asian patients and non-smokers, while KRAS G12C mutations predominate in Western populations and are associated with smoking history.
Co-occurring Mutations Complicate Treatment. NSCLC tumors often carry secondary mutations alongside the primary driver. For example, concurrent TP53 mutations worsen outcomes in EGFR-mutant NSCLC, and STK11 or KEAP1 co-mutations cause primary resistance to immunotherapy in KRAS-mutant tumors, limiting treatment options for many patients.
The Problem of Acquired Resistance. Even when targeted therapies work initially, most patients eventually develop acquired resistance through secondary mutations (like T790M and C797S in EGFR) or through activation of alternative signaling pathways (like MET amplification or HER2 amplification) that bypass the blocked target.
Emerging Rare Targets. Beyond the most common mutations, increasingly rare but targetable alterations are being identified and addressed, including HER2 exon 20 insertions, BRAF V600E mutations, NTRK gene fusions, and FGFR abnormalities. Novel TKIs and antibody-drug conjugates are being developed for each of these subtypes.
Four Generations of EGFR Inhibitors. EGFR-targeted therapy has evolved through four successive generations since gefitinib was first approved in 2003. First-generation drugs (gefitinib, erlotinib) were followed by more potent second-generation agents (afatinib, dacomitinib), then by third-generation osimertinib designed to overcome T790M resistance, and now fourth-generation agents targeting C797S and other compound resistance mutations.
Osimertinib as the New Standard. Third-generation osimertinib has become the first-line standard of care for EGFR-mutant NSCLC due to its high selectivity, strong CNS penetration, and ability to overcome T790M-driven resistance. The LAURA trial demonstrated osimertinib consolidation after chemoradiotherapy extended progression-free survival from 5.6 to 39.1 months in unresectable stage III disease.
Amivantamab-Lazertinib Combination. The MARIPOSA phase 3 trial showed that combining the EGFR-MET bispecific antibody amivantamab with the brain-penetrating TKI lazertinib achieved a median PFS of 23.7 months, versus 16.6 months with osimertinib alone. The final OS analysis showed a more than 12-month survival advantage over osimertinib, establishing this combination as a new first-line option.
Addressing Exon 20 Insertions. EGFR exon 20 insertion mutations resist conventional EGFR-TKIs due to structural similarities with wild-type EGFR. Sunvozertinib (DZD9008) achieved a 53.3% best overall response rate in previously treated patients with this mutation, while amivantamab achieved a 40% ORR with a median PFS of 8.3 months, offering meaningful options for this difficult-to-treat subgroup.
Combining Targeted Therapy and Radiation. Adding stereotactic ablative radiotherapy (SABR) to osimertinib in advanced EGFR-mutant NSCLC extended median PFS to 32.3 months and median OS to 45 months, compared to 18.9 months and 38.6 months respectively with osimertinib alone in historical controls, suggesting local ablation of resistant clones can meaningfully complement systemic targeted therapy.
Lorlatinib Sets New Benchmark for ALK. The CROWN phase 3 trial's long-term results showed that lorlatinib, a third-generation ALK inhibitor, achieved a median PFS that remained unreached after 5 years of follow-up in treatment-naive patients with ALK-positive NSCLC. The 5-year PFS rate reached 60%, a remarkable result compared to crizotinib's 9.1-month median PFS, and the CNS hazard ratio was just 0.06, reflecting near-complete intracranial disease control.
Moving to Earlier-Stage Treatment. The ALINA trial demonstrated that adjuvant alectinib after complete surgical resection of ALK-positive NSCLC (stages IB-IIIA) reduced the risk of disease recurrence or death by 76% compared to platinum-based chemotherapy. This marks a major shift toward using molecularly targeted agents in the curative-intent setting, not just in advanced disease.
Next-Generation ALK Agents. Ensartinib received FDA approval in 2024 for advanced ALK-rearranged NSCLC progressing on earlier-generation TKIs. Investigational NVL-655 achieved a 39% ORR with intracranial responses in heavily pretreated patients and has been granted FDA Breakthrough Therapy Designation, with a head-to-head phase 3 trial against alectinib (ALKAZAR) underway.
Advances in ROS1-Positive NSCLC. Repotrectinib achieved a 79% ORR and 35.7-month median PFS in TKI-naive ROS1 fusion-positive NSCLC. Taletrectinib showed even higher activity in treatment-naive patients with a 91% ORR and 88% intracranial response rate, including efficacy against the resistant G2032R mutation, establishing next-generation options beyond first-line crizotinib.
A Historic Breakthrough. KRAS was considered essentially undruggable for decades due to its smooth protein surface and high GTP affinity. The discovery that KRAS G12C carries a unique cysteine residue enabled development of covalent inhibitors that selectively lock the protein in its inactive GDP-bound state, marking one of the most significant advances in oncology drug development.
Adagrasib Becomes Standard of Care. The KRYSTAL-12 phase 3 trial showed adagrasib achieved superior PFS and ORR compared to docetaxel in previously treated KRAS G12C-mutant NSCLC patients. Based on these results, the 2025 NCCN guidelines designated adagrasib as the preferred second-line regimen for this population, with favorable brain penetration due to its 23-hour half-life.
Combination Strategies Show High Response Rates. Combining KRAS G12C inhibitors with immunotherapy or other targeted agents produced striking results: olomorasib plus pembrolizumab achieved a 77% antitumor response rate regardless of PD-L1 expression, and fulzerasib plus cetuximab showed an 81.8% ORR in untreated patients including 70% in those with brain metastases. The KRAS G12C plus SHP2 inhibitor combination (glecirasib and JAB-3312) achieved a 77.8% ORR as first-line therapy.
Targeting Beyond G12C. While G12C inhibitors have transformed treatment, the KRAS G12D mutation (found in 4% of lung adenocarcinomas but predominantly in pancreatic cancer) remains without approved targeted therapy. Investigational agents HRS-4642 and MRTX1133 have entered clinical evaluation, with MRTX1133 demonstrating nanomolar affinity for KRAS G12D and over 1,000-fold selectivity over wild-type KRAS in preclinical studies.
How ADCs Work. Antibody-drug conjugates (ADCs) combine a tumor-targeting antibody with a potent cytotoxic payload, connected by a linker designed to release the drug preferentially within cancer cells. This 'magic bullet' approach delivers chemotherapy selectively to tumor cells, sparing healthy tissue and potentially overcoming resistance to conventional targeted therapies.
TROP2-Targeting ADCs Show Promise. Dato-DXd (datopotamab deruxtecan), which targets the TROP2 protein found on many cancer cells, significantly improved PFS compared to docetaxel in the TROPION-Lung01 phase 3 trial in previously treated advanced NSCLC patients. A 26% overall response rate was seen, with enhanced activity in non-squamous NSCLC at 30.5% ORR.
HER3-DXd Beats Chemotherapy. Patritumab deruxtecan (HER3-DXd) demonstrated superior outcomes to platinum-based chemotherapy in the HERTHENA-Lung02 phase 3 trial for EGFR-mutated NSCLC that progressed after third-generation EGFR-TKI therapy. The ORR was 35.2% versus 25.3% for chemotherapy, with better PFS at 6, 9, and 12 months across all time points.
MET-Targeted ADC Gains Approval. Telisotuzumab vedotin (Emrelis) received FDA accelerated approval in May 2025 for previously treated c-MET-high non-squamous NSCLC, achieving an ORR of 34.6% in patients with high c-MET expression. This represents the first approved MET-targeted ADC and highlights the expanding role of biomarker-selected ADC therapy in NSCLC.
Bispecific ADC Innovation. Iza-bren (BL-B01D1) represents a novel approach as a first-in-class bispecific ADC targeting both EGFR and HER3 simultaneously. In early clinical evaluation, 85.7% of patients with EGFR exon 20 insertion mutations achieved confirmed partial responses, suggesting dual targeting may overcome the heterogeneous resistance that limits single-target ADCs.
Why Immunotherapy Often Fails in Driver-Mutant NSCLC. Tumors with driver mutations like EGFR or ALK typically have low tumor mutational burden, generating few neoantigens and reducing their visibility to the immune system. These cancers also frequently create an immunosuppressive microenvironment by downregulating MHC expression and promoting infiltration of regulatory T cells and immunosuppressive macrophages.
Non-Adaptive PD-L1 Expression. While some EGFR-mutant tumors express PD-L1, this expression is driven by oncogenic signaling rather than adaptive immune pressure, meaning the tumor has not truly activated the PD-L1 checkpoint to evade immune attack. As a result, blocking PD-L1 does not effectively unmask immune responses in these tumors, explaining the poor results of checkpoint inhibitors when used alone.
VEGFR Inhibition as an Immunotherapy Enhancer. Combining VEGF/VEGFR inhibitors with checkpoint immunotherapy offers a mechanistic solution: anti-VEGF agents can normalize abnormal tumor vasculature, facilitate immune cell entry into the tumor, suppress immunosuppressive cell populations, and enhance dendritic cell maturation, effectively converting immunologically 'cold' tumors into 'hot' ones that are more responsive to immunotherapy.
Triple Combination Therapy. Recent phase 2 and 3 trials have shown that triple combinations of immune checkpoint inhibitors, VEGFR inhibitors, and chemotherapy can provide significant clinical benefits even in EGFR- or ALK-mutant NSCLC. Biomarker-guided patient selection and continued mechanistic study will be needed to establish which patients benefit most from this complex combination approach.
Resistance Remains the Dominant Challenge. Despite remarkable therapeutic advances, acquired resistance to targeted therapies remains the central obstacle in NSCLC treatment. Resistance mechanisms are increasingly complex, involving both on-target mutations (like C797S after osimertinib) and off-target bypass pathways (MET amplification, RAS-MAPK dysregulation), with some patients exhibiting primary resistance even before treatment begins.
Rare Mutations Need Dedicated Solutions. More than a dozen driver gene mutations have been identified in NSCLC, yet targeted therapies for rare alterations like HER2 mutations and MET exon 14 skipping mutations continue to lag behind. The small patient populations make clinical trials challenging, requiring international collaboration and basket trial designs to generate sufficient evidence for regulatory approval.
Importance of Biomarker Testing. Current global biomarker testing rates for KRAS G12C remain below 40%, meaning many patients who could benefit from precision therapies like adagrasib are not receiving them. Expanding access to comprehensive molecular profiling, including next-generation sequencing, is essential to ensure that all eligible patients can access approved targeted treatments.
Toward Personalized Treatment Frameworks. The future of NSCLC treatment lies in individualizing therapy based on precise molecular profiling, resistance mechanism identification after progression, and rational design of combination regimens. Clinical trial participation remains a critical pathway for patients to access cutting-edge treatments and contribute to the evidence base that will benefit future patients.